VCEL Vericel Corp
Price (delayed)
$47.01
Market cap
$2.3B
P/E Ratio
4,701
Dividend/share
N/A
EPS
$0.01
Enterprise value
$2.32B
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured
Highlights
The net income has soared by 106% YoY and by 75% QoQ
The EPS has soared by 104% YoY
The debt rose by 15% YoY and by 3.7% QoQ
The quick ratio has declined by 13% since the previous quarter and by 13% year-on-year
Key stats
What are the main financial stats of VCEL
Market
Valuations
Earnings
Shares outstanding
49.03M
Market cap
$2.3B
Enterprise value
$2.32B
Price to earnings (P/E)
4,701
Price to book (P/B)
9.4
Price to sales (P/S)
10.67
EV/EBIT
1,049.5
EV/EBITDA
162.53
EV/Sales
10.84
Revenue
$214.52M
EBIT
$2.22M
EBITDA
$14.3M
Free cash flow
-$2.19M
Per share
Balance sheet
Liquidity
EPS
$0.01
Free cash flow per share
-$0.04
Book value per share
$5
Revenue per share
$4.41
TBVPS
$7.61
Total assets
$376.84M
Total liabilities
$133.86M
Debt
$95.59M
Equity
$242.98M
Working capital
$153.52M
Debt to equity
0.39
Current ratio
4.5
Quick ratio
4.01
Net debt/EBITDA
1.38
Margins
Efficiency
Dividend
EBITDA margin
6.7%
Gross margin
70.4%
Net margin
0.4%
Operating margin
-1.8%
Return on assets
0.2%
Return on equity
0.3%
Return on invested capital
0.7%
Return on capital employed
0.7%
Return on sales
1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VCEL stock price
How has the Vericel stock price performed over time
Intraday
6.07%
1 week
7.57%
1 month
1.58%
1 year
38.47%
YTD
32.01%
QTD
2.46%
Financial performance
How have Vericel's revenue and profit performed over time
Revenue
$214.52M
Gross profit
$151.07M
Operating income
-$3.82M
Net income
$789,000
Gross margin
70.4%
Net margin
0.4%
The net income has soared by 106% YoY and by 75% QoQ
The net margin has soared by 105% YoY and by 100% QoQ
Vericel's operating margin has soared by 78% YoY
Vericel's operating income has surged by 74% YoY
Growth
What is Vericel's growth rate over time
Valuation
What is Vericel stock price valuation
P/E
4,701
P/B
9.4
P/S
10.67
EV/EBIT
1,049.5
EV/EBITDA
162.53
EV/Sales
10.84
The EPS has soared by 104% YoY
The equity rose by 22% year-on-year and by 3.9% since the previous quarter
VCEL's price to book (P/B) is 2.5% lower than its 5-year quarterly average of 9.1
The revenue has grown by 20% YoY and by 3.2% from the previous quarter
VCEL's price to sales (P/S) is 4.8% higher than its 5-year quarterly average of 9.6
Efficiency
How efficient is Vericel business performance
The ROS has soared by 115% YoY and by 11% from the previous quarter
The ROIC has soared by 114% year-on-year and by 17% since the previous quarter
Vericel's return on assets has surged by 104% YoY and by 100% QoQ
VCEL's ROE has soared by 104% YoY and by 50% from the previous quarter
Dividends
What is VCEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VCEL.
Financial health
How did Vericel financials performed over time
The total assets is 182% higher than the total liabilities
The total assets has increased by 21% YoY and by 6% QoQ
Vericel's total liabilities has increased by 20% YoY and by 9% from the previous quarter
The debt is 61% lower than the equity
The equity rose by 22% year-on-year and by 3.9% since the previous quarter
The debt rose by 15% YoY and by 3.7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.